InvestorQ : How were the quarterly results of Glenmark Life Sciences for Q4?
sarah Leo made post

How were the quarterly results of Glenmark Life Sciences for Q4?

Answer
image
Rashi Mehra answered.
4 weeks ago
Follow

The recently listed Glenmark Life Sciences grew sales revenues 10.04% in the Mar-22 quarter to Rs.514 crore. On a sequential basis, the revenues were flat with downside bias. In terms of revenue verticals in FY22, generic API segment saw revenues grow 12.1% while the CDMO (contract manufacturing) business saw revenues grow 12.4%. Among markets, the regulated market grew revenues by 21.4%, while emerging market fell -6.3%. The board of GSL recommended a final dividend of Rs.10.50/share, taking total dividend to Rs.21/share.

Glenmark Life Sciences

Rs in Crore

Mar-22

Mar-21

YOY

Dec-21

QOQ

Total Income (Rs cr)

₹ 514.06

₹ 467.16

10.04%

₹ 522.50

-1.62%

Net Profit (Rs cr)

₹ 98.90

₹ 104.68

-5.52%

₹ 103.71

-4.64%

Diluted EPS (Rs)

₹ 8.07

₹ 9.71

₹ 8.65

Net Margins

19.24%

22.41%

19.85%

  

For the Mar-21 quarter, the net profit was down -5.52% to Rs.98.9cr, and lower -4.64% on a sequential basis. Certainly, spike in input costs was an issue, but emerging markets business took a dip on sales and profits. EBITDA margins at 28.7% in Q4 were up 10 bps yoy but lower by -770 bps on sequential basis. GLS had ratio of regulated to emerging markets at 72:28. Net margins were 19.24% in Mar-22 quarter compared to 22.41% in Mar-21. The net profit margins were also lower by 61 basis points on a sequential basis.

5 Views